A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Status:
RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.